Related Experiment Video
Updated: Jan 8, 2026

Assessing Mitochondrial Function in Sciatic Nerve by High-Resolution Respirometry
Published on: May 5, 2022
Mitochondrial Dysfunction Drives Oxidative Stress and Energy Imbalance in a Murine Model of Spondyloarthritis
Rodrigo Prieto-Carrasco1, Susana Aideé González-Chávez1, Eduardo Chaparro-Barrera1
1PABIOM Laboratory, Faculty of Medicine and Biomedical Sciences, Autonomous University of Chihuahua, Chihuahua, Mexico.
Abstract:
Joint inflammation and structural damage in spondyloarthritis (SpA) are not fully explained by known immune mechanisms. While mitochondrial dysfunction has been implicated in other rheumatic diseases, such as rheumatoid arthritis and lupus, its role in SpA remains poorly understood. Male DBA/1 mice with spontaneous arthritis (SpAD) and healthy BALB/c mice were compared to assess mitochondrial alterations in joint tissues, isolated mitochondria and cultured fibroblast-like synoviocytes (FLS). Analyses focused on mitochondrial dynamics (fission and fusion) and turnover (biogenesis and mitophagy), bioenergetic function, oxidative stress, and transcriptomic changes associated with mitochondrial function. SpAD induced a coordinated mitochondrial dysfunction in joint tissues characterized by increased fission (Drp1), reduced fusion (Mfn2), and dysregulated turnover processes with elevated mitophagy (PINK1) and biogenesis (PGC-1α). This imbalance led to dysregulation mitochondrial complexes activity, reduced ATP production, and a pronounced increase in oxidative stress. The latter was evidenced by decreased catalase and glutathione peroxidase (Gpx) activity, elevated superoxide dismutase (SOD) activity, and accumulation of 4 hydroxynonenal (4-HNE), highlighting a shift toward a chronic pro-oxidative environment. Similar gene expression changes were observed in cultured FLS. Transcriptomic analysis identified 6,673 differentially expressed genes, including 139 related to mitochondrial function, which reinforces the central role of mitochondrial dysregulation in SpAD pathophysiology. This study is the first to comprehensively characterize mitochondrial dysfunction in a murine model of SpA, identifying it as a potential driver of joint damage. Targeting mitochondrial pathways may offer novel strategies for disease modification in spondyloarthritis.
Insights
Mitochondrial dysfunction drives joint damage in spondyloarthritis (SpA). This study reveals altered mitochondrial dynamics, reduced energy production, and increased oxidative stress in SpA, suggesting new therapeutic targets.
Area of Science:
- Immunology
- Mitochondrial Biology
- Rheumatology
Background:
- Spondyloarthritis (SpA) pathogenesis involves joint inflammation and damage not fully explained by current immune models.
- Mitochondrial dysfunction is implicated in other rheumatic diseases, but its role in SpA is unclear.
Purpose of the Study:
- To comprehensively investigate mitochondrial alterations in a murine model of spontaneous arthritis (SpAD).
- To assess mitochondrial dynamics, bioenergetics, oxidative stress, and transcriptomic changes in SpA joint tissues and cells.
Main Methods:
- Comparison of SpAD mice with healthy controls (BALB/c mice).
- Analysis of joint tissues, isolated mitochondria, and cultured fibroblast-like synoviocytes (FLS).
- Assessment of mitochondrial dynamics (fission/fusion), turnover (biogenesis/mitophagy), bioenergetics, oxidative stress markers, and gene expression.
Main Results:
- SpAD mice exhibited coordinated mitochondrial dysfunction, including increased fission, reduced fusion, and dysregulated turnover.
- Impaired mitochondrial complex activity, reduced ATP production, and elevated oxidative stress were observed.
- Transcriptomic analysis revealed significant changes in mitochondrial function-related genes, confirming dysregulation in SpAD.
Conclusions:
- Mitochondrial dysfunction is a key feature of SpA pathophysiology in this model, potentially driving joint damage.
- Targeting mitochondrial pathways presents a novel therapeutic strategy for spondyloarthritis disease modification.

